BIOMÉRIEUX

VIDAS® HEPATITIS PANELEasy access to testing

for Hepatitis A, B, C and E

05-1

8/ 9

3151

86/0

08/G

B/A

/ B

IOM

ERIE

UX, t

he B

IOM

ERIE

UX lo

go a

nd V

IDAS

are

use

d, p

endi

ng a

nd/o

r reg

ister

ed tr

adem

arks

bel

ongi

ng to

bio

Mér

ieux

, or o

ne o

f its

subs

idia

ries o

r one

of i

ts c

ompa

nies

. Any

ot

her t

rade

mar

k is t

he p

rope

rty o

f its

resp

ectiv

e ow

ner. V

IDAS

app

arat

us is

a u

sed,

pen

ding

and

/or r

egist

ered

des

ign

belo

ngin

g to

bio

Mér

ieux

or o

ne o

f its

com

pani

es /

bio

Mér

ieux

S.A

. RCS

Lyon

673

620

399

/

Phot

os : N

. Bou

chut

/ P

rinte

d in

Fran

ce /

ther

a /

RCS

Lyon

B 3

98 16

0 24

2

1.34 million deaths were caused by viral hepatitis in 2015 1

Mortality from viral hepatitis is increasing, unlike HIV, tuberculosis and malaria 1

Only 9% of HBV-infected people and 20% of HCV-infected people knew their diagnosis in 2015 1

How do you manage on-demand Hepatitis testing?VIDAS® Instrument o� ers � exibility and ease of use to help you deliver actionable results to clinicians

Same-day complete Hepatitis diagnosis● All the essential parameters for e� cient,

di� erential diagnosis of HAV, HBV, HCV and HEV infections

● Just load & go● Single-dose tests for greater � exibility ● Simultaneous testing of di� erent parameters

Cost-e� ective solution● 1 patient = 1 test ● All-inclusive, small-size kits with long shelf life● Automated tests

● Limited calibrations and controls

Your quality, your way● Easily include Hepatitis A & E in your routine

Hepatitis testing ● Control the whole Hepatitis testing process and

streamline your work� ow

Because it makes sense on VIDAS®

Increasing access to e� cient diagnostics is a major step towards eliminating Hepatitis as a public health threat by 2030 2.

bioMérieux S.A. • 69280 Marcy l’Étoile • France • Tel.: + 33 (0)4 78 87 20 00 • Fax: +33 (0)4 78 87 20 90www.biomerieux.com • www.biomerieux-diagnostics.com

REFERENCES1. WHO, Global hepatitis report, 2017.2. WHO, Global Health Sector Strategy on Viral Hepatitis, 2016-2021.

BIOMÉRIEUX

VIDAS® HEPATITIS PANEL REFERENCE TESTS / KIT

HEPATITIS AHAV IgM 30307 30Anti-HAV Total 30312 30

HEPATITIS B

HBs Ag Ultra 30315 60HBs Ag Ultra Con� rmation 30317 30Anti-HBs Total II 30318 60Anti-HBc Total II 30314 60HBc IgM II 30439 30HBe/Anti-HBe 30305 30

HEPATITIS C Anti-HCV 30308 60

HEPATITIS EAnti-HEV IgM 418115 30Anti-HEV IgG 418116 30

VIDAS® HEPATITIS PANELEasy access to testing for Hepatitis A, B, C and E

2 000 000

Num

ber o

f dea

ths

(1)

Year

HepatitisTuberculosis

HIV

Malaria

1 500 000

1 000 000

500 000

2000 2005 2010 2015

HepatitisTuberculosisHIV

Malaria